Aspirin bid
PreclinicalSmall molecule
Aspirin bid is one of 36 small molecule programs targeting Peripheral Arterial Disease. It is currently in Preclinical.
2
Indications
2
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
39 competitors in Peripheral Arterial Disease
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Plavix
SanofiApproved
Brilinta
AstraZenecaApproved
Zyloprim
Jazz PharmaceuticalsApproved
Praluent
RegeneronApproved
Colcrys
Jazz PharmaceuticalsApproved
Pletal
OtsukaApproved
Zetia
OOrganon and Co
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Torisel
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aspirin bid. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity of Pennsylvania